In summary, there is evidence that nicotinic cholinergic drugs may delay progression of PD (Perez, 2015), and thus, the α7 nAChR has been proposed as a target for new medications to treat PD (Quik et al., 2015). The gene discussed is CHRNA7; the disease is Parkinson disease.